| Similar Articles |
|---|
 |
The Motley Fool
March 17, 2005
Stephen D. Simpson |
(G)Nashing of Teeth at Kensey Lower guidance and slower-than-expected FDA approval of TriActiv continue to bedevil this medical device maker.   |
The Motley Fool
August 18, 2005
Stephen D. Simpson |
Kensey Nash Needs to Kick It Up The med-tech company must deliver profit growth if it is to grow or maintain its valuation. |
The Motley Fool
December 17, 2011
Stephanie Baum |
Kensey Nash Opts for Mediation in Royalties Dispute With St. Jude Kensey Nash withdraws guidance; shares plummet. |
The Motley Fool
April 24, 2006
Stephen D. Simpson |
Kensey Nash: Now the Comeback Kid? Strong results from a new device might be reason for optimism. Investors should still keep an eye on the valuations here and err on the side of cheapness. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Don't Hold Your Breath for Kensey Nash It's not over for Kensey Nash -- it will soon be seeing revenue from new partners Medtronic and Zimmer. But the stock's price continues to value this company as a growing med-tech idea. |
The Motley Fool
August 20, 2004
Rich Smith |
Let Kensey Cure Your Portfolio The biomedical products maker is a profit-making machine. This small cap reported outsized profits for fiscal 2004. |
The Motley Fool
August 17, 2007
Rich Smith |
Foolish Forecast: Kensey Turn It Around? Analysts are looking for just a modest sales increase from Kensey Nash, maker of bio-absorbable arterial sealants, but Kensey hasn't met a target yet this year. |
The Motley Fool
October 26, 2004
Rich Smith |
Kensey's Questionable Call Biomedical products maker Kensey Nash forgets that it is worse to dilute and then buy back shares than never to have diluted at all. |
The Motley Fool
August 21, 2006
Stephen D. Simpson |
Kensey Nash Losing the Benefit of the Doubt Med-tech investors won't wait indefinitely for growth. Investors can find better values in this sector if they're willing to roll up their sleeves for some due diligence. |
The Motley Fool
April 22, 2004
Rich Smith |
Kensey Nash Heals Fast Four months was all it took to rejuvinate biomedical products maker Kensey Nash's profit machine. |
The Motley Fool
October 17, 2005
Stephen D. Simpson |
A Busy Day for St. Jude In addition to announcing a major acquisition, St. Jude also reported very solid financial results for the third quarter. Analysts keep raising the bar, and the medical equipment company continues to surpass it. |
The Motley Fool
January 27, 2006
Rich Smith |
Foolish Forecast: Kensey Grow or Not? The medical technology company's problem is that when you hold your margins more or less steady while your revenues also remain roughly the same, well, everything stays the same. In other words, you can't grow earnings. Investors, take note. |
